Evotec SE (EVO)
NASDAQ: EVO · Real-Time Price · USD
3.270
-0.060 (-1.80%)
Dec 1, 2025, 11:34 AM EST - Market open
Evotec SE Revenue
Evotec SE had revenue of 163.89M EUR in the quarter ending September 30, 2025, a decrease of -11.36%. This brings the company's revenue in the last twelve months to 756.33M, down -2.67% year-over-year. In the year 2024, Evotec SE had annual revenue of 796.97M with 1.99% growth.
Revenue (ttm)
756.33M EUR
Revenue Growth
-2.67%
P/S Ratio
1.35
Revenue / Employee
159,563 EUR
Employees
4,740
Market Cap
1.19B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 796.97M | 15.54M | 1.99% |
| Dec 31, 2023 | 781.43M | 29.98M | 3.99% |
| Dec 31, 2022 | 751.45M | 133.41M | 21.59% |
| Dec 31, 2021 | 618.03M | 117.11M | 23.38% |
| Dec 31, 2020 | 500.92M | 54.49M | 12.20% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
EVO News
- 19 days ago - Evotec Receives Milestone Payment from Bristol Myers Squibb Following IND Acceptance in Strategic Protein Degradation Partnership - Accesswire
- 25 days ago - Evotec SE (EVO) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 26 days ago - Evotec SE Reports 9M 2025 Results: Continued Strong Execution on Strategic Priorities - Accesswire
- 26 days ago - In A Landmark Industry Transaction, Evotec Signs Agreement With Sandoz, Resulting In Payments Potentially Over US $650 M Plus Royalties - Accesswire
- 4 weeks ago - Evotec SE to Announce Results for The First Nine Months 2025 on 05 November 2025 - Accesswire
- 5 weeks ago - Evotec Announces Progress in Preclinical Neuroscience Partnership with Bristol Myers Squibb - Accesswire
- 3 months ago - Evotec SE (EVO) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Evotec SE Reports H1 2025 Results: Strong Progress on Strategy Execution - Accesswire